Dr. Hansen should know at least one aspect of lero
Post# of 148263
(Total Views: 792)
Posted On: 04/11/2023 5:47:04 PM
Dr. Hansen should know at least one aspect of leronlimab and it's effect on cancer. He is helping uncover the structure of PI3K. Leronlimab downregulates PI3K.
Quote:
Biopharma companies are trying to develop drugs that target and inactivate these enzymes, known as phosphoinositide 3-kinase, or PI3K for short, because of their role in causing cancers in humans. But to do that, scientists need a detailed blueprint of the enzyme architecture, and UO biochemistry professor Scott Hansen is part of a group uncovering that diagram.
https://around.uoregon.edu/content/chemists-d...ved-cancer
(10)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼